TopFunds

Thermo Fisher Scientific Inc.

NYSE: TMO

Stock price

690 USD

(+0%) TODAY

Medical - Diagnostics & Research
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
4.9
5.1
5.6
7.2
9.2
16
19.5
17.6
15.5
16.5
17.7
13.7%
02Free cash flow per share
6
6.8
8.8
9.3
10
17.1
17.7
17.5
17.9
19
16.7
10.9%
03Dividends per share
0.6
0.6
0.6
0.7
0.8
0.9
1
1.2
1.4
1.6
1.7
11.1%
04Dividends payout, %
12.2%
11.8%
10.7%
9.1%
8%
5.3%
5.1%
6.6%
8.7%
9.2%
9.4%
(2.5)%
PROFIT AND LOSS STATEMENT
05Revenue
16,965
18,274
20,918
24,358
25,542
32,218
39,211
44,915
42,857
42,879
44,557
10.1%
06% Change
-
-
-
-
-
-
-
-
-
-
-
10.1%
07Cost of revenue
(9,127)
(9,692)
(11,239)
(13,370)
(14,198)
(16,191)
(19,577)
(25,904)
(25,663)
(25,151)
(26,318)
11.2%
08Gross profit
7,838
8,582
9,679
10,988
11,344
16,027
19,634
19,011
17,194
17,728
18,239
8.8%
09% Margin
46.2%
47%
46.3%
45.1%
44.4%
49.8%
50.1%
42.3%
40.1%
41.3%
40.9%
44.9% A
10Operating expenses
(5,344)
(5,723)
(6,412)
(7,116)
(7,085)
(8,130)
(9,316)
(10,486)
(9,748)
(10,066)
(10,129)
6.6%
11% of Revenue
(31.5)%
(31.3)%
(30.7)%
(29.2)%
(27.7)%
(25.2)%
(23.8)%
(23.4)%
(22.8)%
(23.5)%
(22.7)%
(26.5)% A
12Operating Income
2,495
2,859
3,267
3,872
4,259
7,897
10,318
8,525
7,446
7,662
8,109
12.5%
13Income tax expense
(43.9)
(1.4)
(201)
(324)
(374)
(850)
(1,109)
(703)
(284)
(657)
(547)
-
14Net Income
1,975
2,022
2,225
2,938
3,696
6,375
7,725
6,950
5,995
6,335
6,737
13.1%
15% Margin
11.6%
11.1%
10.6%
12.1%
14.5%
19.8%
19.7%
15.5%
14%
14.8%
15.1%
14.4% A
16Shares Outstanding
401.9
397.4
398
406
403
399
397
394
388
383
377
(0.6)%
17EPS Basic
5
5.1
5.6
7.3
9.2
16.1
19.6
17.7
15.5
16.6
17.8
13.6%
18EPS Diluted
4.9
5.1
5.6
7.2
9.2
16
19.5
17.6
15.5
16.5
17.7
13.7%
19EBITDA
4,040
4,252
5,054
6,196
7,023
10,108
11,969
11,942
11,195
11,800
11,466
11%
% Margin
23.8%
23.3%
24.2%
25.4%
27.5%
31.4%
30.5%
26.6%
26.1%
27.5%
25.7%
26.6% A
20Net Interest Income (expense)
(384.3)
(421.2)
(511)
(530)
(452)
(488)
(493)
(454)
(612)
(576)
(426)
1%
21Net Debt / EBITDA
3
3.7
3.9
2.7
2.3
1.2
2.7
2.3
2.5
2.4
2.6
2.7 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
452.1
786
1,335
2,103
2,399
10,325
4,477
8,524
8,083
4,019
9,852
36.1%
23Short-term investments
-
-
-
-
-
-
-
-
-
1,561
253
-
24Accounts receivable
2,545
3,049
3,879
4,595
4,952
6,472
8,945
9,427
9,664
9,626
10,566
15.3%
25Other current assets
752.5
973
1,236
922
1,172
1,131
1,640
1,644
1,760
1,953
2,611
13.3%
26Inventory
1,992
2,213
2,971
3,005
3,370
4,029
5,051
5,634
5,088
4,978
5,425
10.5%
27Total Current Assets
5,741
7,021
9,421
10,625
11,893
21,957
20,113
25,229
24,589
22,137
28,707
17.5%
Non-Current Assets
28Net property, plant & equipment
2,449
2,578
4,047
4,165
5,448
6,687
9,864
10,873
11,004
10,795
10,565
15.7%
29Long-term investments
39
37
34
53
35
65
73
155
59
560
-
-
30Other non-current assets
32,605
36,272
43,167
41,389
41,005
40,343
65,073
60,897
63,074
63,829
71,071
8.1%
31Total Non-Current Assets
35,093
38,887
47,248
45,607
46,488
47,095
75,010
71,925
74,137
75,184
81,636
8.8%
Total Assets
40,834
45,908
56,669
56,232
58,381
69,052
95,123
97,154
98,726
97,321
110,343
10.5%
LIABILITIES
Current Liabilities
32Accounts payable
822.2
926.2
1,428
1,615
1,920
2,175
2,867
3,381
2,872
3,079
3,622
16%
33Short-term debt
1,052
2,097
2,135
1,271
843
2,812
2,803
5,851
3,872
2,475
3,533
12.9%
34Other current liabilities
2,272
1,842
3,485
3,261
3,434
5,317
7,766
7,778
7,268
7,778
8,034
13.5%
35Total Current Liabilities
4,146
4,866
7,048
6,147
6,197
10,304
13,436
17,010
14,012
13,332
15,189
13.9%
Non-Current Liabilities
36Long-term debt
11,420
15,492
18,883
17,728
17,647
19,733
33,536
30,222
32,552
30,300
35,852
12.1%
37Other non-current liabilities
3,918
4,010
5,325
4,771
4,862
4,498
7,174
5,774
5,320
4,018
5,766
3.9%
38Total Non-Current Liabilities
15,338
19,502
24,208
22,499
22,509
24,231
40,710
35,996
37,872
34,318
41,618
10.5%
39Total Liabilities
19,484
24,368
31,256
28,646
28,706
34,535
54,146
53,006
51,884
47,650
56,807
11.3%
SHAREHOLDERS` EQUITY
40Common stock
411.9
415.1
428
432
434
437
439
441
442
444
445
0.8%
41Retained earnings / (deficit)
12,142
13,927
15,914
18,696
22,092
28,116
35,431
41,910
47,364
53,102
59,156
17.2%
42Accumulated other comprehensive income / (loss)
(1,997)
(2,636)
(2,003)
(2,498)
(2,679)
(2,807)
(2,329)
(3,099)
(3,224)
(2,697)
(2,448)
2.1%
43Noncontrolling interests
-
-
-
-
-
10
184
170
107
87
129
-
44Total shareholders' equity
21,350
21,540
25,413
27,586
29,675
34,517
40,977
44,148
46,842
49,671
53,536
9.6%
45Total Liabilities and shareholders' Equity
40,999
45,908
56,589
56,232
58,381
69,052
95,123
97,154
98,726
97,321
110,343
10.4%
46Total Debt
12,472
16,628
21,008
18,990
18,490
22,545
36,339
36,073
36,424
32,775
39,385
12.2%
47Net Debt
12,020
15,842
19,649
16,875
16,070
12,220
31,862
27,549
28,341
28,766
29,533
9.4%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
1,975
2,022
2,225
2,938
3,696
6,375
7,725
6,950
5,995
6,335
6,737
13.1%
49Depreciation & amortization
1,688
1,758
2,033
2,267
2,277
2,325
2,592
3,381
3,406
3,108
2,780
5.1%
50Share-based compensation expense
125
133.5
159
181
181
196
230
307
278
301
310
9.5%
51Changes in working capital and other assets
(971.7)
(757)
(412)
(843)
(1,181)
(607)
(1,004)
(1,484)
(1,273)
(1,077)
(2,009)
7.5%
52Net cash flows from operating activities
2,817
3,156
4,005
4,543
4,973
8,289
9,543
9,154
8,406
8,667
7,818
10.8%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(422.9)
(444.4)
(508)
(758)
(926)
(1,474)
(2,523)
(2,243)
(1,479)
(1,400)
(1,525)
13.7%
54Purchases of investments / marketable securities
6.1
(54.9)
(15)
-
-
-
(8)
(15)
-
(3,396)
(383)
-
55Proceeds from maturities of marketable securities
12
81.2
22
-
-
-
8
15
70
1,770
1,565
62.8%
56Other investing activities
(682.6)
(5,114)
(7,228)
(495)
(561)
(36)
(19,409)
84
(3,733)
(2,815)
(3,704)
18.4%
57Net cash flows from investing activities
(1,087)
(5,532)
(7,729)
(1,253)
(1,487)
(1,510)
(21,932)
(2,159)
(5,142)
(5,841)
(4,047)
14%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(500)
(1,250)
1,068
(500)
(1,500)
(1,500)
(2,000)
(3,000)
(3,000)
(4,000)
(3,000)
19.6%
59Dividends paid, net
(240.6)
(238.4)
(237)
(266)
(297)
(337)
(395)
(455)
(523)
(583)
(636)
10.2%
60Debt issuance (repayments), net
(1,942)
4,174
3,026
(1,556)
(717)
2,750
8,911
654
(155)
(2,403)
5,347
-
61Other financing activities
65.6
175.1
(3)
85
(604)
46
65
(9)
56
194
90
3.2%
62Net cash flows from financing activities
(2,617)
2,861
3,854
(2,237)
(3,118)
959
6,581
(2,810)
(3,622)
(6,792)
1,801
-
63Increase (decrease) in cash and cash equivalents
(898)
334.1
550
756
305
7,914
(5,845)
4,046
(440)
(4,057)
5,839
-
64Cash and equivalents, ending balance
466
786.2
1,361
2,117
2,422
10,336
4,491
8,537
8,097
4,040
9,879
35.7%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
2,394
2,712
3,497
3,785
4,047
6,815
7,020
6,911
6,927
7,267
6,293
10.2%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Thermo Fisher Scientific Inc. (TMO) financial statements and performance

Explore Thermo Fisher Scientific Inc. (TMO) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.